# The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.

Study · id `cardio:ct-nct01828359` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01828359](<https://clinicaltrials.gov/study/NCT01828359>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01828359

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

## Technical summary

Registry record NCT01828359. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 199 participants (enrolled count; ClinicalTrials.gov record NCT01828359, source copy `cardio:ctgov-nct01828359-2013-04-10`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01828359, source copy `cardio:ctgov-nct01828359-2013-04-10`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01828359, source copy `cardio:ctgov-nct01828359-2013-04-10`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01828359, source copy `cardio:ctgov-nct01828359-2013-04-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01828359-2013-04-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
- Condition: Hypertension
- Intervention (Drug): Amosartan® tab
- Intervention (Drug): Cozaar® plus pro tab
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 9197aa64715b2452ae2a19872783d67c9f91c5266c44c334c555d1d777833000
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
